Scientists believe that Alzheimer's disease-related damage to the brain begins many years before the symptoms of memory loss emerge. One protein thought to contribute to the progression of memory loss and Alzheimer’s is beta-amyloid, a sticky protein that can clump together to form “plaques” in the brain. Plaques may block communication between brain cells and trigger the brain to discard disabled cells. The A4 trial believes that starting treatment with solanezumab very early will help slow the onset and progression of memory loss by ridding the brain of excess beta-amyloid. This study tests the investigational drug, solanezumab, in older adults who are at risk for future memory loss.
The study lasts about three years and three months and involves monthly IV infusions of solanezumab or placebo, as well as occasional memory tests, brain scans, and blood draws. Solanezumab is an antibody that is thought to inhibit the buildup of beta-amyloid in the brain. This treatment is free of charge. You will be compensated for your time.
Participants must be fairly healthy adults age 65-85 with normal memory and thinking abilities. Participants who are enrolled into the treatment portion of the study will have beta-amyloid markers on a brain scan that suggest Alzheimer's disease may develop in the future. It is not required that you have a family history of Alzheimer's disease to participate. Participation will include monthly visits to Butler and IV infusions. If you are interested in learning more about the A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease, please call (401) 455-6403 or send an e-mail to: memory@butler.org. Ask about the "A4 Study."
We encourage those interested in A4 to visit the A4 study website and learn more about importance of this groundbreaking landmark study. You may also be interested in viewing the A4 Study Brochure or downloading the A4 Flyer.